No Data
No Data
Insider Sale: SVP of $KPTI Sells 2,793 Shares
Express News | Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $54
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Cuts Target Price to $56
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Karyopharm Therapeutics Inc : H.c. Wainwright Adjusts Target Price to $56 From $7 to Reflect 1-for-15 Reverse Stock Split
ColdJoke : HK 6996. That revenue mainly goes to Antengene. We really got sucked badly and going to delist![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
.